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THALIDOMIDE is teratogenic for women and certain species ofanimal (McBride,
1961; Lenz, 1962; Pfeiffer and Kosenow, 1962; Somers, 1962; Spencer, 1962;
Bignami, Bovet, Bovet-Nitti and Rosmati, 1962; Giroud, Tuchmann-Duplessis
and Mercier-Parot, 1962; Di Paolo, 1963). The drug induced local tumours in 3
out of23 mice which received repeated subcutaneous injections (Roe andMitchley,
1963). Alkylnitrosoureas are known to be potent both as teratogens and as
carcinogens (Druckrey, Ivankovi6 and Preussmann, 1965; Ivankovic, Druckrey
and Preussmann, 1965; Kreybig, 1965). A single doseofethylnitrosourea injected
intravenously (80 mg./kg. body weight) into 3 female rats at the fifteenth day of
pregnancy induced malformations of the paws in all 21 rats which were subse-
quently born (Druckrey, Ivankovic and Preussmann, 1966). Four rats which
survived beyond weaning developed malignant neurinomata of the trigeminal
nerve or bronchial and lumbosacral plexuses, and the fifth an intracranial tumour.
The present experiment was designed to investigate whether thalidomide given
to pregnant mice would induce tumours in the offspring.
MATERIALS AND METHODS
Mice.-Chester Beatty random-bred stock mice were used. They were housed
in metal cages andgiven a cubed diet (Diet 86, Messrs. Dixon & Sons, Ware, Herts.)
and water ad libitum.
Chemical agents.-Thalidomide was obtained from the Distillers Co. Ltd.
(Biochemicals), Speke, Liverpool, and arachis oil from Damoore Ltd.
Experimental
Ten male and 10 female young adult Chester Beatty stock mice were injected
subcutaneouslywith 7-5mg. (approximately 150mg./kg. body weight) thalidomide
in 0 1 ml. arachis oil and mated respectively with 10 female and 10 male untreated
mice. Daily injections of 7-5 mg. thalidomide were continued to the appropriate
member of a pair until a litter was born. No litter was born to 2 pairs in which
the male was treated or to 2 pairs in which the female was treated. The 8 treated
females which produced litters received between 22 and 26 injections (165-195 mg.
thalidomide) before parturition, and the 8 treated males between 23 and 41 injec-
tions (172.5-307.5 mg. thalidomide) before the litters were born.
The litters were examined soon after birth for malformations. Thereafter,
they were inspected daily until they were weaned at 4 weeks. After weaning the
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examined once each week and more cursorily on the intervening days. Autopsies
were carred out on mice which died during the experiment and onthose which were
killed because they were sick. The last survivors were killed when they were 66
weeks old.
Parents were killed after their litters were weaned. The 2 treated males and
2 treated females of non-littering pairs received 220 injections of thalidomide.
During the eleventh month one ofthe females developed a spindle cell sarcoma at
the injection site (Roe and Mitchley, 1963). One male died before the eleventh
month and the other 2 animals were killed after 12 months without developing
tumours.
RESULTS
One male mouse, the offspring of a thalidomide-treated male, which died
within 24 hours of birth had clumped toes on its forefeet. There were no other
malformations.
The incidence oftumours is shown in Table I. A comparison was made with
the incidence of spontaneous tumours in Chester Beatty stock mice (Roe, 1965).
The tumour incidence in the offspring of female mice given repeated sub-
cutaneous injections of thalidomide during pregnancy was no higher than that in
untreated mice of the same strain or that in the offspring of parents where the
father was treated with thalidomide.
TABLE I.-Tumours in CB Stock Mice of which one Parent WaS Treated with
Thalidomide, and in Untreated and Solvent-treated Controls.
Mother treated S
with thalido-
mide
(165-195 mg.)
(Progenykilled d
or dying be.
tween 0 and
15 months)
Father treated 9
with thalido-
mide
(172 5-307.5
mg.)
(Progenykilled <
or dying be-
tween 0 and
15 months)
Untreated or
solvent.
treated CB
Stock mice
which died
between 0and
18 months*
* From Roe, 1965.
No. No.
born weaned
19 . 13
35 . 27
17 . 14
22 . 16
No. examined
post-mortem
53
233
No. with
malignant
lymphoma
2
5
3
0
16
No. with
lung
adenoma
1
2
0
0
5
No. with
hepatoma
0
Other
tumours
0 . -
0
1
0 1 Mammary
adenocarcinoma
41 . 17 . 14 4 Skin tumours
1 Subcut.
adenocarcinoma
1 Tumour of
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DISCUSSION
Malformations of the skeleton and brain have been described in embryos of
several strains ofmice where pregnant females received equivalent or smaller doses
of thalidomide by oral intubation or in the food (Giroud et al., 1962; Di Paolo,
1963; Di Paolo, Gatzek and Pickren, 1964). In the present experiment only
1 mouse, the offspring of a thalidomide-treated male, was malformed. This
abnormality was presumably unrelated to thalidomide treatment of the father.
In the test reported here the failure to induce either teratogenic or carcinogenic
effects by administration ofthalidomide may be attributed to the insensitivity of
the mice. In view ofthe results quoted above the failure cannot be attributed to
inadequacy of dosage unless subcutaneous administration is less effective than
oral administration. Confirmation of the negative result in other strains and in
tests where the oral route of administration is employed is desirable.
SUMMARY
The tumour incidence in the offspring of female Chester Beatty stock mice
given daily subcutaneous injections of7-5 mg. thalidomide (total dose 165-195 mg.)
from before mating until parturition, was low. It was no higher than that in the
offspring of parents where the father received thalidomide or than that in un-
treated mice of the same strain. Only 1 mouse, the offspring of a thalidomide-
treated male, was malformed.
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